Peter T. Sage, PhD
Scientific Advisory Board Member
Dr. Peter T. Sage is an Associate Professor of Medicine at Harvard Medical School and an Associate Immunologist at Brigham and Women’s Hospital. With a distinguished career in immunology, Dr. Sage’s research focuses on the complex interplay between T cells and B cells in health and disease, with particular emphasis on autoimmune conditions and transplantation. His groundbreaking work on follicular regulatory T cells (Tfr) and follicular helper T cells (Tfh) has significantly advanced our understanding of how these subsets modulate immune responses, driving innovation in cellular immunotherapy.
As a member of the Scientific Advisory Board, Dr. Sage plays a critical role in advancing cutting-edge cell and gene therapy programs. His expertise is particularly instrumental in helping us design strategies to stabilize and engineer regulatory T cells (Tregs) for addressing autoimmune diseases. His insights ensure that our initiatives are rooted in rigorous, clinically relevant science, fostering transformative outcomes for patients.
Dr. Sage earned his PhD in Immunology from Harvard Medical School and has received numerous accolades for his contributions to the field. His unwavering commitment to bridging foundational research with therapeutic innovation aligns with our mission to transform healthcare and shape a future free from chronic diseases.
Chia-Lin Hsu, PhD
Scientific Advisory Board Member
Dr. Chia-Lin Hsu is a Professor at the Institute of Microbiology and Immunology at National Yang Ming Chiao Tung University (NYCU) in Taiwan. With a distinguished career spanning both academia and industry, Dr. Hsu’s research focuses on the intricate interplay between immunity and metabolism. Her pioneering work on metabolite transporters and their regulatory roles in T cell biology has significantly advanced our understanding of how immune cells can be modulated for therapeutic applications.
As a member of the Scientific Advisory Board, Dr. Hsu brings invaluable expertise to the development of next-generation cell therapies. Her deep knowledge of T cell and macrophage biology plays a pivotal role in shaping innovative strategies to enhance immune cell functions through genetic engineering and metabolic interventions. These advancements are critical for developing next-generation cellular therapies targeting autoimmunity through novel and previously untapped mechanisms. Furthermore, her insights are instrumental in advancing antigen-specific multi-targeting technologies, which we aim to establish as a cornerstone of our FAST CGT platform.
Dr. Hsu earned her PhD in Immunology from Duke University and completed her postdoctoral training at Genentech. She later served as a Senior Scientist at the Center of Therapeutic Innovation at Pfizer. Recognized with multiple Outstanding Research Awards, Dr. Hsu’s contributions to immunological science highlight her dedication to translating fundamental discoveries into transformative therapies. Her expertise aligns seamlessly with our mission to pioneer groundbreaking treatments that redefine immunotherapy and inspire a future free from chronic diseases.
Ivan Dzhagalov, PhD
Scientific Advisory Board Member
Dr. Ivan Dzhagalov is an Associate Professor at the Institute of Microbiology and Immunology at National Yang Ming Chiao Tung University (NYCU) in Taiwan. With a distinguished career in immunology, Dr. Dzhagalov’s research is centered on macrophage biology, delving into macrophage development and the mechanisms that drive phagocytosis and efferocytosis. His pioneering work on the development and functional specialization of thymic macrophages and the regulation of efferocytosis in both physiological and pathological conditions have provided critical insights into immune regulation and novel therapeutic opportunities.
As a member of the Scientific Advisory Board, Dr. Dzhagalov brings unparalleled expertise in translating macrophage biology into innovative cellular therapies. His deep understanding of efferocytic pathways plays a pivotal role in advancing strategies to modulate immune responses, facilitate the clearance of autoantigens, and tackle the pathogenesis of systemic lupus erythematosus (SLE). He is leading the charge in reimagining therapeutic approaches to develop macrophage-based cellular therapies with disease-modifying potential for SLE patients. His research also underpins the design of transformative macrophage therapies targeting autoimmunity and other inflammatory conditions, extending the capabilities of our FAST CGT platform to deliver groundbreaking solutions.
Dr. Dzhagalov earned his MD from Trakia University Medical School, his PhD in Immunology from Duke University, and completed his postdoctoral training at the University of California, Berkeley. With numerous publications and accolades to his name, Dr. Dzhagalov’s contributions to immunological science reflect his ability to bridge foundational research with therapeutic innovation. His creativity and expertise are central to our commitment to transforming cutting-edge cellular biology into accessible, next-generation therapies that improve the lives of patients worldwide.